Tag: membranes

苏格兰格拉斯哥, June 09, 2026 (GLOBE NEWSWIRE) -- 万益特（Vantive），作为一家拥有70年肾脏护理创新历史的重要脏器疗法公司，今日发布两项突破性临床研究：采用 泰诺佳^® 透析器的 HDx 疗法，与在线血液透析滤过（OL-HDF）相比，在全因死亡率和主要心血管结局方面*表现相似（统计学上非劣效）。^1,2随机对照试验MOTheR 研究、真实世界研究CONCORDIA中期数据，已于 2026 年 6 月 3–6 日在苏格兰格拉斯哥举办的第 63届欧洲肾脏协会（ERA）大会上发布。

BALLERUP, Denmark, June 04, 2026 (GLOBE NEWSWIRE) -- LiqTech International, Inc. (NASDAQ: LIQT), a clean technology company specializing in advanced ceramic filtration solutions, today announced the pricing of its underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $1.00 per share for aggregate gross proceeds of approximately $20 million, prior to deducting underwriting discounts, commissions and other offering expenses. In addition, the Company has granted the underwriter a 45-day option to purchase up to an additional 3,000,000 shares of common stock at the public offering price per share, less the underwriting discounts and commissions, to cover over-allotments, if any. The offering is expected to close on June 8, 2026, subject to satisfaction of customary closing conditions.

Warsaw, Poland – June 03, 2026 – JJP Biologics, ("JJPBio" or the "Company") a clinical-stage, immune-focused biotech that engineers precision antibodies to correct derailed immune pathways that drive autoimmune diseases and cancer, today announces positive interim data from its ongoing Phase 1b trial evaluating nebaprubart, also known as JJP-1212, its investigational potential first-in-class anti-CD89 antagonist, in patients diagnosed with Linear IgA Disease (LAD), a rare autoantibody-mediated skin disease.

BALLERUP, Denmark, Aug. 13, 2025 (GLOBE NEWSWIRE) -- LiqTech International, Inc. (Nasdaq: LIQT) ("LiqTech"), a clean technology company that manufactures and markets highly specialized filtration technologies, today announced its financial results for the second quarter of 2025 for the period ended June 30, 2025.

Management to Host Conference Call on Wednesday, August 13, 2025, at 9:00 a.m. Eastern time